A5038274711- Formal Methods in Verification
- Software Testing and Debugging Techniques
- Lung Cancer Treatments and Mutations
- Model-Driven Software Engineering Techniques
- Cancer therapeutics and mechanisms
- Petri Nets in System Modeling
- Business Process Modeling and Analysis
- Logic, programming, and type systems
- Access Control and Trust
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Software Reliability and Analysis Research
- Advanced Software Engineering Methodologies
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
CEA LIST
2021-2022
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
2021
CEA Paris-Saclay
2021
Laboratoire d'Informatique de Paris-Nord
2015-2018
Université Sorbonne Paris Nord
2015-2018
Université Paris Cité
2015-2017
Centre National de la Recherche Scientifique
2015-2017
Sorbonne Paris Cité
2015-2017
This paper studies the analysis and parameter synthesis problems for Parametric Timed Automata (PTA) with properties in Linear-time Temporal Logic (LTL). It introduces a series of variations Nested Depth-First Search (NDFS). We first study LTL model checking problem PTA. Based on careful parametric zones, we introduce new layered NDFS approach to checking. integrate this several techniques prune search space. In particular, apply subsumption abstraction PTA time. also propose heuristics...
Abstract Background This study aimed to evaluate the efficacy and side effects of first-line afatinib treatment in a real-world setting Vietnam. Methods retrospective was conducted across nine hospitals Advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients who received as therapy between April 2018 June 2022 were included, patient medical records reviewed. Key outcomes overall response rate (ORR), time-to-treatment failure (TTF), tolerability....
Background: Afatinib is indicated for advanced-stage non-small-cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) and uncommon mutations. However, real-world studies on this topic are limited. This study aimed to evaluate afatinib as first-line therapy locally advanced metastatic NSCLC EGFR Patients methods: A retrospective included 92 patients compound mutations, treated therapy. were followed up evaluated every 3 months or when symptoms of progressive disease arose. The...
ABSTRACT Introduction The role of afatinib in the first‐line treatment EGFR‐mutant advanced non–small cell lung cancer (NSCLC) patients has been proven through clinical trials and real‐world studies. However, additional data on effectiveness with brain metastases are lacking. Methods NSCLC were retrospectively reviewed across nine centers Vietnam from April 1, 2018 to June 2022. primary endpoints included central nervous system progression‐free survival (CNS‐PFS) overall (OS). secondary...
Parametric timed automata are a powerful formalism to reason about, model and verify real-time systems in which some constraints unknown, or subject uncertainty. Parameter synthesis using parametric is very sensitive the state space explosion problem. To mitigate this problem, we propose two new exploration orders, i. e., "ranking strategy" "priority based strategy", compare them with existing strategies. We consider both complete parameter synthesis, counterexample where analysis stops as...
Parametric timed automata (PTA) allow the specification and verification of systems incompletely specified, or featuring timing constants that may change either in design phase, at runtime. The behavioral cartography PTA (BC) relies on idea covering a bounded parameter domain with tiles, i.e., parts which discrete behavior is uniform. This achieved by iterating inverse method (IM) (yet uncovered) integer valuations (points) parametric domain: given reference point, IM generalizes...
Abstract Background: This study aimed to evaluate the efficacy and side effects of first-line afatinib treatment in a real-world setting Vietnam. Methods: retrospective was conducted across nine hospitals Advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients who received as therapy between April 2018 June 2022 were included, patient medical records reviewed. Key outcomes overall response rate (ORR), time-to-treatment failure (TTF), tolerability....